We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company
LJPC

Delisted

LJPC was delisted on the 19th of August, 2022.

Back to rankings

41 hedge funds and large institutions have $53.9M invested in La Jolla Pharmaceutical Company in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less funds holding

Funds holding: 45 → 41 (-4)

24% less capital invested

Capital invested by funds: $70.4M → $53.9M (-$16.6M)

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
41
Holders Change
-4
Holders Change %
-8.89%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
2
Increased
8
Reduced
17
Closed
6
Calls
$47K
Puts
–
Net Calls
+$47K
Net Calls Change
-$55K

Top Buyers

Rank Fund Capital Flow
1
HP
HealthInvest Partners
Sweden
+$2.17M
2
ONB
Old National Bancorp
Indiana
+$161K
3
Renaissance Technologies
Renaissance Technologies
New York
+$122K
4
OSAM
O'Shaughnessy Asset Management
Connecticut
+$67.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$217K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$149K
3
Millennium Management
Millennium Management
New York
-$141K
4
GC
Globeflex Capital
California
-$133K
5
Two Sigma Investments
Two Sigma Investments
New York
-$118K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$30.6M – – –
RI
2
RTW Investments
New York
$7.42M – – –
HP
3
HealthInvest Partners
Sweden
$4.04M +$2.17M +558,000 +79%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.63M – – –
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$1.85M -$72.5K -18,624 -3%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$1.48M -$48.5K -12,441 -3%
BlackRock
7
BlackRock
New York
$1.33M -$32.3K -8,297 -2%
KT
8
Kevin Tang
$766K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$650K +$4.34K +1,114 +0.5%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$392K -$17.1K -4,391 -3%
Millennium Management
11
Millennium Management
New York
$327K -$141K -36,283 -26%
State Street
12
State Street
Massachusetts
$316K – – –
Fidelity Investments
13
Fidelity Investments
Massachusetts
$288K -$510 -131 -0.1%
Northern Trust
14
Northern Trust
Illinois
$257K +$2.19K +562 +0.7%
HCM
15
Hollencrest Capital Management
California
$256K -$7.79K -2,000 -2%
GC
16
Globeflex Capital
California
$187K -$133K -34,188 -37%
Renaissance Technologies
17
Renaissance Technologies
New York
$183K +$122K +31,400 +120%
OSAM
18
O'Shaughnessy Asset Management
Connecticut
$163K +$67.7K +17,385 +52%
Morgan Stanley
19
Morgan Stanley
New York
$138K -$2.95K -758 -2%
ONB
20
Old National Bancorp
Indiana
$132K +$161K +41,284 New
WA
21
WealthTrust Axiom
Pennsylvania
$81K – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$71K +$41.5K +10,647 +92%
RWM
23
Ritholtz Wealth Management
New York
$53K +$6.56K +1,685 +11%
SSA
24
Schonfeld Strategic Advisors
New York
$49K -$41.3K -10,600 -41%
RPCA
25
Running Point Capital Advisors
California
$32K – – –
1
2

LJPC Hedge Fund Activity: Q2 2022 in Review

41 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2022, worth a combined $53.9M — down 24% from $70.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LJPC and 2 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was HealthInvest Partners, adding an estimated $2.17M. The largest seller was Citadel Advisors, exiting entirely with an estimated $217K sold.

  • 41 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2022, down from 45 in Q1 2022.
  • Funds reported $53.9M of La Jolla Pharmaceutical Company stock for Q2 2022, down 24% quarter-over-quarter.
  • 2 funds opened new La Jolla Pharmaceutical Company positions in Q2 2022 and 6 closed out, a net change of -4 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q2 2022 was HealthInvest Partners, an estimated $2.17M added.
  • The largest La Jolla Pharmaceutical Company seller in Q2 2022 was Citadel Advisors, an estimated $217K sold.

Based on aggregated 13F filings for Q2 2022.